Kiadis Pharma

Kiadis Pharma B.V. devel­ops new treat­ment options for end-stage can­cer patients who may ben­e­fit from a bone mar­row trans­plant.

The company’s lead prod­uct, ATIR™, is designed to expand the donor pool for end-stage blood can­cer patients by sig­nif­i­cant­ly dimin­ish­ing the risk of graft-ver­sus-host dis­ease in mis­matched bone mar­row trans­plants.

Portfolio: MedSciences Capital II B.V.

Current prod­uct devel­op­ment stage: phase III clin­i­cal tri­al. Listed on Euronext Amsterdam and Brussels